Hi Elysian I was thinking that the next report would disappoint...

Hi Elysian
I was thinking that the next report would disappoint the market because of this last report,
But you seem to think otherwise is that correct.


Thankyou
_____________________________________________

EXTRACT below

11 June 2004
SciGen Limited
SciGen to Manufacture Hep B Vaccine and Increase Market
Coverage
Asia-Pacific rights for SciGen to develop and market a therapeutic Vaccine developed
from Sci-B-Vac for the treatment of hepatitis.
SciGen intends to initiate manufacturing in India with its local partner, Shreya Biotech, and
will consider another Asian manufacturing site at a later stage.
SciGen has secured the assistance of an expert technical team, formerly of Savient, to
supervise the process of technology transfer which will take approximately six months.
This will result in a temporary interruption to supply of the vaccine and a consequent effect
on SciGen�fs revenue which SciGen expects to be offset by other benefits from the new
license agreement.